Cardiff Lexington Announces Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary

Cardiff Lexington (CDIX) reports strong financial results for the fourth quarter and full year 2023, showing significant revenue growth, improved profitability, and positive balance sheet highlights. The company's operating income, net income, and EBITDA all experienced substantial increases, with a focus on expanding their healthcare subsidiary, Nova Ortho and Spine, to capitalize on market demand.

Positive

• Strong revenue growth of 11% in 2023 compared to the previous year.
• Operating income increased by 33% to $5.2 million in 2023.
• Net income surged by 156% to $3.0 million in 2023.
• Significant improvement in gross profit margins and EBITDA.
• Total assets increased by 55% to $20.7 million, with shareholders' equity rising by 142% to $0.7 million.
• Positive working capital achieved by the end of 2023.
• Expansion of Nova Ortho and Spine with the opening of eleven locations, targeting key population centers in Florida and the broader southeast United States.
• Implementation of a reverse stock split to meet listing requirements for potential uplisting to a major U.S. exchange in the second quarter of 2024.

Negative

• None.

- Full Year 2023 Highlighted by Strong Revenue Growth and Profitability -

FT. LAUDERDALE, FL / ACCESSWIRE / March 28, 2024 / Cardiff Lexington Corporation (OTC PINK:CDIX) announced today financial results for its fourth quarter and year ended December 31, 2023.

Fourth Quarter 2023 Financial Highlights

• 4Q23 revenue of $2.4 million was consistent with revenue of $2.5 million in 4Q22
• 59% gross profit margin in 4Q23 increased from 58% in 4Q22
• Operating income was $415,000, or 17% of sales, which compares to $677,000, or 27% of sales in 4Q22
• Net income increased 107% to $0.2 million from a loss of $3.5 million in 4Q22

Full Year 2023 Financial Highlights

• 11% growth in revenue to $11.9 million compared to $10.7 million in FY22
• 70% gross profit margin in FY23 increased from 62% in FY22
• Operating income increased 33% to $5.2 million, or 44% of sales, which compares to $3.9 million, or 37% of sales in FY22
• Net income increased 156% to $3.0 million from a loss of $5.4 million in FY22
• 53% increase in FY23 EBITDA to $5.2 million compared to FY22

Balance Sheet Highlights at December 31, 2023

• 55% increase in total assets to $20.7 million compared to $13.3 million at December 31, 2022
• 142% increase in shareholders' equity to $0.7 million compared to a negative shareholders' equity of $1.7 million at December 31, 2022

Positive working capital compared to a negative working capital at December 31, 2022

Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, "2023 was a very strong year for our business highlighted by strong revenue growth of 11% and significantly improved profitability with 26% net income. Operating income increased 33% to $5.2 million in 2023. At the center of this growth is Nova Ortho and Spine, our healthcare subsidiary that provides orthopedic healthcare services to the uninsured patient population. With a unique, asset-light business model we drove significant economic returns and a collection rate of 99.8% - far outpacing the industry average. Nova Ortho and Spine is ideally positioned to benefit from unprecedented demand growth in this market fueled by an aging patient population and rising number of personal injury accidents.

Mr. Cunningham continued, "To capitalize on this opportunity, we're intently focused on building a strong management team and strategically expanding our footprint of Nova Ortho and Spine locations with a near term goal of targeting key population centers throughout Florida and the broader southeast United States. To that end, we've enhanced our executive team with the hiring of a new Chief Financial Officer and Chief Accounting Officer whose backgrounds and skills are closely aligned with our business goals. We've also appointed a new Managing Director of Nova Ortho and Spine with an extensive medical and business background to help facilitate our growth. To date, we've opened a total of eleven Nova Ortho and Spine locations, including our tenth location in Florida in Port St. Lucie, and our first location outside of Florida in Valdosta, Georgia. The opening of the Valdosta location marks a key inflection point in our growth strategy, and we're energized by the demand and opportunity that we're seeing in the market for our services as we expand into the broader southeast United States, with the long-term goal of eventually expanding nationwide.

"Subsequent to the close of the quarter, we implemented a reverse stock split as part of our strategy to meet listing requirements and qualify for an uplisting to a major U.S. exchange during the second quarter of 2024. Uplisting to a major U.S. exchange would allow us to increase access to dedicated funding and reduce the cost of capital to support our growth strategy. To that end, preferred shareholders are currently converting their preferred shares to common stock to increase the number of total outstanding shares and the market value of the public float.

"In 2023, we demonstrated our ability to provide best-in-class care for an underserved population of the orthopedic market and create attractive economic returns for shareholders. We look forward to efficiently expanding our operations and bringing our services and solutions to more patients as we continue to execute on our growth strategy and drive increased value in 2024 and beyond."

-----

About Cardiff Lexington Corporation:

Cardiff Lexington Corporation is a holding company focused on locating, acquiring, and building middle market, niche companies, primarily in the healthcare industry. Fundamental to the Cardiff Lexington strategy is the service-based partnership culture which emphasizes core values, teamwork, accountability, and performance.

A substantial majority of the Company's revenue is derived from Nova Ortho and Spine, PLLC, which operates a group of regional primary specialty and ancillary care facilities throughout Florida that provide traumatic injury victims with a full range of diagnostic and surgical services, primary care evaluations, interventional pain management, and specialty consultation services.

For more information on Cardiff Lexington Corporation, you may access the company's website at https://cardifflexington.com/

FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's business, the Company's liquidity position, the Company's ability to obtain new business, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur.

Cardiff Lexington Investor Relations
investorsrelations@cardifflexington.com
(800) 628-2100 ext. 705

or

IMS Investor Relations
cardifflexington@imsinvestorrelations.com
(203) 972-9200

CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2023 AND 2022
(UNAUDITED)

		For the Three Months Ended								For the Years Ended
		December 31,								December 31,
		2023				2022				2023				2022
Total revenue		$	2,376,502			$	2,538,262			$	11,853,266			$	10,693,196
Total cost of sales			971,217				1,077,616				3,560,624				4,060,034
Gross profit			1,405,285				1,460,646				8,292,642				6,633,162
Operating expenses
Depreciation expense			9,412				5,783				20,777				23,132
Selling, general and administrative			981,209				777,757				3,076,820				2,703,141
Total operating expenses			990,621				783,540				3,097,597				2,726,273
Income from continuing operations			414,664				677,106				5,195,045				3,906,889
Other income (expense)
Other income (expense)			(50,000	)			150,250				(49,795	)			150,250
Gain on debt refinance and forgiveness			115,058				-				115,448				1,397,271
Penalties and fees			(5,000	)			(2,063,916	)			(53,000	)			(2,063,916	)
Interest expense			(192,567	)			296,885				(1,956,266	)			(6,387,309	)
Amortization of debt discounts			(41,854	)			(4,703	)			(136,518	)			(253,823	)
Total other income expense			(174,363	)			(1,621,484	)			(2,080,131	)			(7,157,527	)
Net income (loss) before discontinued operations			240,301				(944,378	)			3,114,914				(3,250,638	)
Loss from discontinued operations			-				(2,267,736	)			-				(2,178,883	)
Income (Loss) from disposal of discontinued operations			6,485				(328,353	)			(86,520	)			-
Net income (loss)		$	246,786			$	(3,540,467	)		$	3,028,394			$	(5,429,521	)

CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF DECEMBER 31, 2023 AND DECEMBER 31, 2022
(UNAUDITED)

		December 31,
		2023				2022
						(Restated)
ASSETS
Current assets
Cash		$	866,943			$	219,085
Accounts receivable-net			13,305,254				6,603,920
Prepaid and other current assets			5,000				5,000
Total current assets			14,177,197				6,828,005
Property and equipment, net			34,661				55,439
Land			540,000				540,000
Goodwill			5,666,608				5,666,608
Right of use - assets			289,062				218,926
Due from related party			4,979				4,979
Other assets			33,304				30,823
Total assets		$	20,745,811			$	13,344,780
LIABILITIES, MEZZANINE EQUITY AND DEFICIENCY IN STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable and accrued expense		$	2,047,131			$	1,915,920
Accrued expenses - related parties			4,733,057				3,750,557
Accrued interest			620,963				350,267
Right of use - liability			157,669				142,307
Due to director and officer			120,997				123,192
Notes payable			2,136,077				15,809
Convertible notes payable, net of debt discounts of $24,820 and $46,797, respectively			3,807,030				3,515,752
Net liabilities of discontinued operations			237,643				151,123
Total current liabilities			13,860,567				9,964,927
Other liabilities
Notes payable			144,666				139,789
Operating lease liability - long term			119,056				84,871
Total liabilities			14,124,289				10,189,587
Mezzanine equity
Redeemable Series N Senior Convertible Preferred Stock - 3,000,000 shares authorized, $0.001 par value, stated value $4.00, 868,056 shares issued and outstanding at December 31, 2023 and 2022			3,891,439				3,125,002
Redeemable Series R Senior Convertible Preferred Stock - 5,000 shares authorized, $0.001 par value, stated value of $1,200, 165 shares issued and outstanding at December 31, 2023 and 2022			307,980				274,982
Redeemable Series X Senior Convertible Preferred Stock - 5,000,000 shares authorized, $0.001 par value, stated value of $4.00 par value; 375,000 shares issued and outstanding at December 31, 2023 and 2022			1,690,685				1,500,000
Total Mezzanine Equity			5,890,104				4,899,984
Stockholders' equity (deficit)
Series B Preferred Stock - 3,000,000 shares authorized, $0.001 par value, stated value of $4.00, 2,139,478 and 2,131,328 shares issued and outstanding at December 31, 2023 and 2022, respectively			8,537,912				8,525,312
Series C Preferred Stock - 500 shares authorized, $0.001 par value, stated value of $4.00, 123 shares issued and outstanding at December 31, 2023 and 2022			488				488
Series E Preferred Stock - 1,000,000 shares authorized, $0.001 par value, stated value $4.00, 155,750 and 150,750 shares issued and outstanding at December 31, 2023 and 2022, respectively			623,000				603,000
Series F-1 Preferred Stock - 50,000 shares authorized, $0.001 par value, stated value $4.00, 35,752 shares issued and outstanding at December 31, 2023 and 2022			143,008				143,008
Series I Preferred Stock - 15,000,000 shares authorized, $0.001 par value, stated value $4.00, 14,885,000 issued and outstanding at December 31, 2023 and 2022			59,540,000				59,540,000
Series J Preferred Stock - 2,000,000 shares authorized, $0.001 par value, stated value $4.00, 1,713,584 shares issued and outstanding at December 31, 2023 and 2022			6,854,336				6,854,336
Series L Preferred Stock - 400,000 shares authorized, $0.001 par value, stated value $4.00, 319,493 shares issued and outstanding at December 31, 2023 and 2022			1,277,972				1,277,972
Common Stock; 7,500,000,000 shares authorized, $0.001 par value; 24,065 and 10,997 shares issued and outstanding at December 31, 2023 and 2022, respectively			1,804,799				824,793
Additional paid-in capital			(9,365,982	)			(8,581,265	)
Accumulated deficit			(68,684,115	)			(70,932,435	)
Total stockholders' equity			731,418				(1,744,791	)
Total liabilities, mezzanine equity and stockholders' equity		$	20,745,811			$	13,344,780

CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2023 AND 2022
(UNAUDITED)

The following table reconciles Net income (loss) before discontinued operations (a GAAP measure) to EBITDA (a non-GAAP measure)

		For the Three Months Ended								For the Years Ended
		December 31,								December 31,
		2023				2022				2023				2022
EBITDA (1)
Net income (loss) before discontinued operations		$	240,301			$	(944,378	)		$	3,114,914			$	(3,250,638	)
Add:
Interest			192,567				(296,885	)			1,956,266				6,387,309
Taxes			0				0				0				0
Depreciation			9,412				5,783				20,777				23,132
Amortization			41,854				4,703				136,518				253,823
EBITDA (1)		$	484,134			$	(1,230,777	)		$	5,228,475			$	3,413,626

(1) EBITDA is a non-GAAP measure defined as Earnings Before Interest, Income Tax, Depreciation and Amortization.

SOURCE: Cardiff Lexington Corporation

View the original press release on accesswire.com

FAQ

What was Cardiff Lexington 's revenue growth in 2023?

Cardiff Lexington reported an 11% growth in revenue to $11.9 million in 2023 compared to $10.7 million in the previous year.

What was the net income increase for Cardiff Lexington in 2023?

Cardiff Lexington 's net income increased by 156% to $3.0 million in 2023 from a loss of $5.4 million in the previous year.

How many Nova Ortho and Spine locations did Cardiff Lexington open in 2023?

Cardiff Lexington opened a total of eleven Nova Ortho and Spine locations in 2023.

What strategic move did Cardiff Lexington make to potentially uplist to a major U.S. exchange?

Cardiff Lexington implemented a reverse stock split as part of their strategy to meet listing requirements for a potential uplisting to a major U.S. exchange in the second quarter of 2024.

What was the percentage increase in total assets for Cardiff Lexington at the end of 2023?

Cardiff Lexington experienced a 55% increase in total assets to $20.7 million at the end of 2023 compared to $13.3 million at the end of 2022.